BREAKING NEWS: Today AstraZeneca released results of the AZD7442 PROVENT Phase III pre-exposure prophylaxis trial. This is the first trial to show significant effectiveness of monoclonal antibodies in pre-exposure protection against #COVID19 in a high-risk population. 
The study showed a 77% reduction in the development of symptomatic #COVID19. One-time shots are expected to provide 6-12 months of protection.
Immunocompromised individuals, which include #CLL patients, have not always had a robust response to the #COVID19 vaccine. This is huge progress for gaining protection against #COVID19 in our #CLL community.
Read the write up from Dr. Brian Koffman about this news at cllsociety.org/2021/08/azd744…
@AstraZenecaUS @CllIreland @CLLAdvocates @bloodcancer_uk @LeukaemiaCareUK @LLSusa @lymphoma @alisonedye
• • •
Missing some Tweet in this thread? You can try to
force a refresh
